CAPR - Capricor Therapeutics Inc

https://www.capricor.com

Hold Momentum: Bearish

Recent News

Shareholders of Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights - CAPR - Capricor Therapeutics ( NASDAQ:CAPR )

Benzinga • 0 minutes ago • score: 0.13

NEW YORK, Sept. 15, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. CAPR. Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapies for the treatment and prevention of a broad spectrum of diseases. The company is headquartered in Beverly Hills, California.

52W High

$23.40

52W Low

$4.05

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.73

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-2.73

EV/Revenue (<3 favorable)

13.92

P/S (TTM) (<3 favorable)

23.01

P/B (<3 favorable)

2.94

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

16.79%

Institutions (25–75% balanced)

30.56%

Shares Outstanding

45,717,000

Float

40,185,200

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

13,392,200

Gross Profit (TTM)

-53,933,480

EPS (TTM)

-1.59

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-5.48%

ROE (TTM) (>15% strong)

-1.20%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.08

Momentum

Bearish momentum

Value

-0.4313

-0.4537

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025